Purpose: To investigate the long-term effect of oral acyclovir administered during the first 6 months after penetrating keratoplasty (PK) for herpetic eye disease (HED).
INTRODUCTION
The protective effect of oral acyclovir on herpetic eye disease (HED) recurrences was established in eyes without grafts 1,2 as well as after penetrating keratoplasty (PK). [3] [4] [5] [6] In 2003, the results of a prospective randomized multicenter trial on the effect of oral acyclovir after PK for herpetic keratitis were published. 7 In this former study, oral acyclovir administered during the first 6 months after PK significantly reduced HED recurrences during the first 2 postoperative years. In this article we describe the 5-year follow-up of the same population.
MATERIALS AND METHODS
For the original trial, all successive patients with corneal opacities attributed to HED who were scheduled for PK were considered for enrollment. Patients were randomized for double-blind treatment with 400 mg acyclovir or identical placebo tablets twice per day during 6 months following PK. Sixty-eight patients were included: 35 received acyclovir and 33 received placebo tablets. Patients could be included for only 1 eye. 7 In this former study, the study medication was stopped in the occurrence of an event (defined as HED recurrence or rejection) and was replaced by therapeutic doses of valacyclovir.
For the present study we undertook a 5-year follow-up of the same population. All patients were scheduled for visits at 36 and 60 months postoperatively, according to the national follow-up program of keratoplasties performed in the Netherlands. In this follow-up program, apart from many other data, all events such as operative procedures, rejections, and infections occurring after keratoplasty are recorded. Data are sent to a central database and can be extracted for each transplanting center. In most cases, patients were seen at shorter intervals and on an emergency basis when indicated. Data regarding these clinical events were derived from event forms completed according to the national follow-up program as well as from medical charts.
Events were classified as epithelial or stromal recurrences, kerato-uveitis, or rejection according to description and diagnosis of the treating physician. Rejection was also scored as an event, because differentiation between a rejection and a HED recurrence cannot be based on clinical grounds only. When oral acyclovir was prescribed during these 5 years of follow-up, this was scored, as was medical or surgical treatment for elevated intraocular pressure. At 5 years postoperatively, the visual acuity (VA) was scored as well as the clarity and vascularization of the graft. When a regraft was indicated, this was scored, as was the reason for the regraft.
Statistical analysis was performed with the statistical packages SPSS (version 11) and SAS (version 8.2). The monthly incidence of events during follow-up was determined with Poisson regression analysis. The first events occurring during follow-up were plotted in a Kaplan-Meier curve ( Figure 1 ). VA was analyzed with mixed-model ANOVA using LogMAR; time (baseline, 1 year, and 5 years), treatment, and their interactions were the explanatory factors.
RESULTS
For 47 of the 68 patients enrolled for the original study, we were able to complete the 5-year follow-up. Of these 47 patients, 24 were from the acyclovir group and 23 from the placebo group; 16 were lost to follow-up; 2 died; and 3 were excluded because of a regraft.
After the 5-year follow-up, the mean LogMAR VA was 0.44 in the acyclovir group (Snellen equivalent: 0.36) and 0.56 in the placebo group (Snellen equivalent: 0.3). This difference in VA was not statistically significant (NS).
When HED events other than rejection episodes (i.e., only epithelial and stromal keratitis) and kerato-uveitis were analyzed as one group, there was a statistically significant lower monthly event rate in the acyclovir group (P = 0.037) ( Table 1 ). There were no statistically significant differences in rate ratios between the two groups with regard to all types of clinical events (epithelial and stromal keratitis, kerato-uveitis, and rejection episodes), either individually or when all four types of events were combined. Figure 1 shows the event-free interval in both groups, for all events (excluding graft rejection episodes), during the 5-year follow-up. One patient from the placebo group developed vascularization of the graft in 2 quadrants. Six patients developed a graft that was not clear: 2 from the placebo group and 4 from the acyclovir group. Eight eyes (5 in the acyclovir group) developed elevated intraocular pressure, for which glaucoma medication was prescribed. Of these patients, 2 (both from the acyclovir group) had a trabeculectomy. Three patients received a regraft: 1 from the placebo group, after a trauma, and 2 from the acyclovir group because of a rejection episode (15 and 27 months postoperatively). The low incidence of these events (vascularization, graft clarity, glaucoma events, regrafts) precluded proper statistical analysis ( Table 2) .
After the initial 6-month use of the protocol medication, oral acyclovir was prescribed again for 12 patients during the 5-year follow-up: 3 patients in the acyclovir group (mean dose of 666 mg, twice per day for 42 months) and 9 in the placebo group (888 mg, twice per day for 28 months) (NS).
DISCUSSION
In a former trial involving this patient population, when systemic antiviral medication was administered during the first 6 postoperative months, a significant reduction in cultureproven HSV-related events during the first 2 years after transplantation was noted. 7 During the 2 year follow-up period there were 3 culture-proven HED events in the acyclovir group and 9 in the placebo group. Survival analysis of the probability of remaining free from recurrences revealed a significantly reduced risk of recurrent HED in the acyclovir-treated group (P = 0.026). 7 Note. ACV, acyclovir group; PLAC, placebo group; HED, herpetic eye disease; KU, kerato-uveitis; 1,2,3: total of epithelial HED, stromal HED, and KU; 1,2,3,4: total of epithelial HED, stromal HED, KU, and rejection; NA, not applicable.
The current report describes the 5-year follow-up study of the same population. Considering the total clinically evident HED recurrences (epithelial HED, stromal HED, and keratouveitis) for the 5-year follow-up, we found a statistically significant lower monthly event rate in the acyclovir group (P = 0.037). In penetrating corneal grafts for HED, a distinction between a rejection episode or HED recurrence in cases of an anterior chamber reaction cannot be made on clinical grounds only. For this reason, during the initial 2-year follow-up study, an anterior chamber tap was mandatory in the study protocol. 7 When all 4 types of events (epithelial HED, stromal HED, kerato-uveitis, and rejection) were combined to compare the effect in the 2 study groups, no statistically significant difference was detected. It was not possible to determine whether this lower rate of events had any influence on the survival of grafts, because of the low incidence of graft failure (regrafts and/or unclear grafts).
There were no clinically significant differences in VA. The low incidence of vascularization of the graft, use of glaucoma medication, regraft, and unclear graft precluded statistical analysis; thus, it was not possible to determine statistically significant differences.
The incidence of unclear grafts during the 5-year followup is relatively low. For all patients recorded in the national database as having a clear cornea and low VA, a reason for the VA reduction other than corneal (e.g., retinal) was scored. The re-introduction rate of oral acyclovir after cessation of the study medication in cases of a clinical HED recurrence may have contributed to the high rate of clear grafts. There was no statistical difference between the two groups with regard to oral acyclovir use after cessation of the study medication.
Other investigators found the highest rates of epithelial recurrences and rejections during the first 12 months after transplantation. 4, 8, 9 In a retrospective study on the effect of antiviral therapy after corneal transplantation for HED, Moyes found that graft failure was statistically significantly associated with recurrences of herpetic keratitis during the first 12 months after transplantation. 4 This higher rate of rejection and recurrences during the postoperative year was the reason for choosing a 6-month prophylaxis.
Whether eyes after PK for HED are protected from recurrences and rejection in the long term by the use of oral acyclovir remains to be established, preferably by means of a randomized trial with a long-term follow-up. Our results suggest a protection against clinically evident HED recurrences during the 5 years following PK. We were not able to prove protection against graft rejection or to prove a longer graft survival. There appears to be justification for acyclovir prophylaxis, on the basis of our former 7 and present study as well as the safety of the drug and data presented by other authors [3] [4] [5] [6] from studies of acyclovir after PK and the Herpetic Eye Disease Study. 1 The optimal duration of prophylaxis still is not clear and needs to be clarified, but despite the short, 6-month duration of acyclovir prophylaxis used in our study, we detected a significant effect on clinical HED recurrences during the first 5 years of follow-up. 
